Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarXT Pharmacokinetics Study in Healthy Adults
NCT07118215Phase 1Completed
- Sponsor
- Karuna Therapeutics
- Start
- Sep 2025
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of xanomeline in schizophrenia (4 arms), sponsored by Karuna Therapeutics. Primary endpoints: Maximum observed plasma concentration and Area under the plasma concentration-time curve. Started Sep 2025; status: completed.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07118215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07118215.